Evenity (Romosozumab) Geriatric (65+) Dosing

The 210 mg Monthly Dose Does Not Change for Patients Over 65

Romosozumab is dosed at 210 mg subcutaneously once every month for 12 doses regardless of age. The FDA-approved labeling specifies no geriatric dose modification [1]. Each monthly administration consists of two separate 105 mg/1.17 mL prefilled syringe injections given consecutively into the abdomen, thigh, or upper arm. Both injections must be completed within the same clinic visit.

This fixed-dose approach reflects population pharmacokinetic analyses from the FRAME and ARCH registration programs. Body weight, age, and creatinine clearance did not meaningfully alter romosozumab exposure in models that included patients up to 89 years old [2]. The Phase 3 ARCH trial enrolled postmenopausal women with a median age of 74 years, making the efficacy and safety dataset directly applicable to the geriatric population rather than extrapolated from younger cohorts [3].

One practical note for clinicians managing frail older adults: romosozumab is administered in a healthcare setting. Patients do not self-inject. This removes adherence barriers common with daily or weekly oral bisphosphonates, where studies report 12-month persistence rates below 50% in adults over 70 [4].

Why the ARCH Trial Population Validates Geriatric Use

The ARCH trial (N=4,093) compared 12 months of romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture [3]. The median participant age was 74 years. Over 60% of enrolled patients were 75 or older.

At 24 months (12 months of romosozumab plus 12 months of alendronate), the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared with continuous alendronate (6.2% vs. 11.9%, P<0.001) [3]. Hip fracture risk fell by 38% (2.0% vs. 3.2%, P=0.02) [3]. These reductions persisted across age subgroups, including patients over 75.

Pre-specified subgroup analyses in ARCH showed consistent fracture-risk reduction in patients aged 75 and older, with no signal of diminished efficacy at advanced age [3]. The FRAME trial (N=7,180), which compared romosozumab to placebo before both groups transitioned to denosumab, enrolled a somewhat younger cohort (mean age 70.9 years) but confirmed the pattern: 73% reduction in new vertebral fractures at 12 months, with benefits sustained through 24 months after the denosumab transition [5].

These numbers matter in clinical context. A 75-year-old woman with a prior vertebral fracture has a 20% probability of sustaining another fracture within 2 years if left on oral bisphosphonates alone. Romosozumab offers the fastest bone density gains of any approved osteoporosis therapy, with lumbar spine BMD increasing 13.3% at 12 months versus 5.0% with alendronate in the ARCH population [3].

Cardiovascular Screening Before Starting Romosozumab in Older Adults

The FDA boxed warning on romosozumab states that the drug may increase the risk of myocardial infarction, stroke, and cardiovascular death [1]. This warning originated from a numerical imbalance in the ARCH trial: 2.5% of romosozumab patients experienced a major adverse cardiovascular event (MACE) during the first 12 months compared with 1.9% of alendronate-treated patients [3].

This imbalance demands careful pre-treatment cardiovascular assessment, particularly in geriatric patients who carry higher baseline cardiovascular risk. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months [1].

Before prescribing romosozumab to a patient over 65, clinicians should complete a structured cardiovascular risk assessment. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend calculating 10-year ASCVD risk using the pooled cohort equations and reviewing recent cardiac history [6]. The Endocrine Society position statement suggests that patients with established atherosclerotic cardiovascular disease or multiple major risk factors may be better served by denosumab or zoledronic acid as first-line agents [7].

"Romosozumab should be reserved for patients at very high fracture risk who do not have recent cardiovascular events or established cardiovascular disease," states the 2020 AACE/ACE clinical practice guideline for postmenopausal osteoporosis [6].

The decision matrix is simple for most geriatric patients. If 10-year ASCVD risk is low to moderate and no MI or stroke occurred in the past year, romosozumab remains a first-line option for very high fracture risk. If cardiovascular disease is established, choose a different agent.

Renal Function: No Dose Change, but Monitoring Intensifies

Romosozumab does not undergo renal elimination. As a monoclonal antibody, it is cleared through intracellular catabolism via the reticuloendothelial system [1]. No dose adjustment is required at any level of renal impairment, including in patients on dialysis [1].

The clinical concern is different. Patients with eGFR <30 mL/min/1.73m² face substantially higher risk of hypocalcemia during romosozumab therapy [8]. The mechanism is straightforward: romosozumab stimulates rapid bone formation, pulling calcium from the circulation into the mineralizing skeleton. Patients with CKD stage 4-5 often have impaired 1,25-dihydroxy vitamin D synthesis and secondary hyperparathyroidism, making their calcium homeostasis already precarious.

For geriatric patients with eGFR <30:

• Check 25-hydroxyvitamin D before initiation; replete to a minimum of 30 ng/mL
• Ensure daily calcium intake of 1,000 to 1 to 200 mg (dietary plus supplemental)
• Monitor serum calcium at 2 weeks after the first dose and periodically thereafter
• Watch for symptoms of hypocalcemia: perioral tingling, muscle cramps, QTc prolongation

In the ARCH trial, severe renal impairment (CrCl <30 mL/min) was an exclusion criterion, so real-world data in this subgroup is limited [3]. Post-marketing surveillance and case series have documented symptomatic hypocalcemia in CKD patients receiving romosozumab, reinforcing the need for proactive calcium monitoring in this population [8].

Drug-Drug Interaction Burden in the Polypharmacy Patient

Romosozumab has no known clinically significant drug-drug interactions [1]. As a monoclonal antibody targeting sclerostin, it does not interact with cytochrome P450 enzymes, drug transporters, or protein binding sites. This pharmacologic profile makes it unusually clean for the geriatric polypharmacy setting.

The practical interactions that matter are pharmacodynamic, not pharmacokinetic. Concurrent use of systemic glucocorticoids (prednisone 5 mg or more daily) suppresses osteoblast activity and may blunt romosozumab's anabolic effect [9]. Patients on chronic corticosteroids should still receive romosozumab if fracture risk warrants it, but clinicians should attempt to minimize steroid dose.

Thiazide diuretics reduce urinary calcium excretion and could theoretically exacerbate the hypercalcemia risk during the bone-formation window. In practice, this interaction is rarely clinically significant, but checking serum calcium at baseline and after the first dose is reasonable in patients taking hydrochlorothiazide 25 mg daily or higher [10].

Loop diuretics (furosemide, bumetanide) increase urinary calcium loss and may worsen the hypocalcemia risk, particularly in patients with CKD. Monitor accordingly.

Fall Risk and Fracture Prevention Beyond the Drug

Prescribing romosozumab to a 78-year-old with severe osteoporosis while ignoring fall risk is treating half the equation. Falls cause fractures. In adults over 65, approximately 95% of hip fractures result from falls [11].

A comprehensive geriatric fracture prevention plan running alongside romosozumab therapy should include: vision assessment and correction, medication review for fall-promoting drugs (sedatives, anticholinergics, alpha-blockers, opioids), home safety evaluation, balance and strength training (the Otago Exercise Programme reduced falls by 35% in community-dwelling older adults), and vitamin D repletion to 30 to 50 ng/mL [12].

"The pharmacologic treatment of osteoporosis should always be coupled with non-pharmacologic fall prevention strategies," according to the 2022 Endocrine Society guideline on osteoporosis management [7]. The greatest BMD gain in the world does not help a patient who fractures a hip falling over a loose rug.

The 12-Month Limit and Mandatory Sequential Therapy

Romosozumab's anabolic effect follows a self-limiting trajectory. Sclerostin antibody blockade produces a surge in bone formation markers (P1NP) that peaks at month 6 and returns toward baseline by month 12 [13]. Bone resorption markers (CTX) initially decline, then begin to rise after month 6. This coupling pattern means that extending romosozumab beyond 12 months would yield diminishing returns and is not supported by trial data.

The FDA label limits treatment to 12 monthly doses [1]. After the final romosozumab injection, transition to an antiresorptive agent is mandatory. Without it, the bone density gained during the anabolic window will be lost.

Two transition options have supporting evidence in older adults:

Romosozumab to denosumab. The FRAME extension showed that romosozumab followed by denosumab produced 17.6% lumbar spine BMD gain at 24 months. The transition is smooth: administer the first denosumab 60 mg injection one month after the last romosozumab dose [5].

Romosozumab to alendronate (or zoledronic acid). The ARCH trial demonstrated sustained fracture reduction with this sequence. Zoledronic acid 5 mg IV once yearly is a practical choice in geriatric patients with GI intolerance or adherence challenges, since it requires only a single annual infusion [14].

"Failure to follow romosozumab with an antiresorptive results in rapid BMD loss, similar to discontinuation of teriparatide without bisphosphonate follow-up," warns the Endocrine Society clinical practice guideline [7].

Choosing between denosumab and a bisphosphonate involves weighing the rebound fracture risk of denosumab discontinuation (which itself requires bisphosphonate bridging if stopped) against the simplicity of moving directly to a bisphosphonate after romosozumab. For a patient over 80 who may remain on antiresorptive therapy indefinitely, denosumab's reliable efficacy and every-6-month dosing schedule may be preferable despite the discontinuation complexity.

Deprescribing Considerations in Late Life

For patients over 85 or those with limited life expectancy (<2 years), the risk-benefit calculation for initiating a new 12-month osteoporosis treatment shifts. Romosozumab requires monthly clinic visits for a year, followed by indefinite antiresorptive therapy. The time-to-benefit for hip fracture reduction with romosozumab-to-alendronate in ARCH was approximately 12 months [3].

The question is not whether romosozumab works in a 90-year-old. It does. The question is whether the 12-month treatment burden, cardiovascular risk exposure, and monthly visit schedule align with that patient's goals of care. A patient with advanced dementia in a nursing home has different priorities than an active 90-year-old living independently.

The American Geriatrics Society Beers Criteria do not specifically list romosozumab, but recommend reassessing osteoporosis therapy in the context of overall treatment goals and life expectancy [15]. Shared decision-making is the correct approach here, not a rigid age cutoff.

Monitoring Schedule for Geriatric Patients on Romosozumab

A practical monitoring timeline for patients 65 and older receiving romosozumab:

Before starting: Baseline DXA (spine and hip), 25-hydroxyvitamin D, serum calcium, phosphorus, eGFR, CBC, 10-year ASCVD risk assessment, dental examination (ONJ risk is low but not zero with prior bisphosphonate exposure).

Month 1 (after first dose): Serum calcium check at 2 weeks if eGFR <30 or vitamin D was deficient at baseline. Symptom review for injection site reactions (5.2% in ARCH vs. 3.7% alendronate) [3].

Months 2 through 12: Monthly injection visits. Reassess cardiovascular symptoms at each visit. Repeat serum calcium at month 3 and month 6 if renal impairment is present.

Month 12: Final romosozumab dose. Plan antiresorptive transition. Repeat DXA at 12 months is optional but provides baseline for the antiresorptive phase.

Month 13: Initiate denosumab or bisphosphonate. Do not leave any gap between the last romosozumab injection and the start of the antiresorptive agent.

The monthly visit schedule doubles as a geriatric touchpoint for fall assessment, medication reconciliation, and nutritional status review. Each romosozumab injection appointment is an opportunity to reinforce non-pharmacologic fracture prevention.